Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
PHASE1
The main objective of this trial is to evaluate the pharmacokinetics (PK) o...
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
PHASE1
The main objective of this trial is to evaluate the pharmacokinetics (PK) o...
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
PHASE2
The study aims to compare and assess the dose response of 3 selected doses ...
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
PHASE3
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart c...